Cost-effectiveness and resource use analysis of patients with asthma before and after treatment with mepolizumab in a real-life setting

To define the cost-effectiveness and health resource use of mepolizumab in a cohort of patients with severe eosinophilic asthma in real-life conditions in Spain.